Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
32.42
+0.21 (0.67%)
At close: Jun 8, 2026, 4:00 PM EDT
32.39
-0.02 (-0.08%)
After-hours: Jun 8, 2026, 4:10 PM EDT
Harmony Biosciences Holdings Employees
Harmony Biosciences Holdings had 293 employees as of December 31, 2025. The number of employees increased by 25 or 9.33% compared to the previous year.
Employees
293
Change (1Y)
25
Growth (1Y)
9.33%
Revenue / Employee
$3,068,625
Profits / Employee
$496,980
Market Cap
1.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 293 | 25 | 9.33% |
| Dec 31, 2024 | 268 | 22 | 8.94% |
| Dec 31, 2023 | 246 | 46 | 23.00% |
| Dec 31, 2022 | 200 | 20 | 11.11% |
| Dec 31, 2021 | 180 | 30 | 20.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Iovance Biotherapeutics | 975 |
| ADMA Biologics | 647 |
| Lakefront Biotherapeutics NV | 558 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Stoke Therapeutics | 170 |
HRMY News
- 12 days ago - Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire
- 25 days ago - Harmony Biosciences Holdings Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Harmony Biosciences price target raised to $29 from $25 at Truist - TheFly
- 4 weeks ago - Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.02B - TheFly
- 4 weeks ago - Harmony Biosciences Holdings Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Harmony Biosciences Holdings Slides: Q1 2026 - Filings
- 4 weeks ago - Harmony Biosciences Holdings Earnings release: Q1 2026 - Filings
- 4 weeks ago - Harmony Biosciences Holdings Quarterly report: Q1 2026 - Filings